Clearbridge Investments LLC Has $697.69 Million Stake in CVS Health Corporation $CVS

Clearbridge Investments LLC trimmed its holdings in CVS Health Corporation (NYSE:CVS) by 2.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 8,791,761 shares of the pharmacy operator’s stock after selling 240,075 shares during the period. Clearbridge Investments LLC’s holdings in CVS Health were worth $697,688,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Caitong International Asset Management Co. Ltd grew its stake in CVS Health by 407.2% in the third quarter. Caitong International Asset Management Co. Ltd now owns 350 shares of the pharmacy operator’s stock valued at $26,000 after acquiring an additional 281 shares during the period. Ares Financial Consulting LLC acquired a new position in CVS Health in the fourth quarter valued at about $29,000. Dogwood Wealth Management LLC grew its stake in CVS Health by 93.7% in the fourth quarter. Dogwood Wealth Management LLC now owns 370 shares of the pharmacy operator’s stock valued at $29,000 after acquiring an additional 179 shares during the period. GoalVest Advisory LLC acquired a new position in CVS Health in the fourth quarter valued at about $32,000. Finally, MidAtlantic Capital Management Inc. acquired a new position in CVS Health in the fourth quarter valued at about $35,000. 80.66% of the stock is owned by institutional investors and hedge funds.

CVS Health Stock Performance

Shares of NYSE CVS opened at $96.11 on Friday. The stock has a 50 day moving average price of $84.13 and a 200 day moving average price of $80.03. CVS Health Corporation has a 52 week low of $58.50 and a 52 week high of $98.43. The company has a debt-to-equity ratio of 0.78, a quick ratio of 0.66 and a current ratio of 0.87. The stock has a market capitalization of $122.62 billion, a PE ratio of 42.34, a price-to-earnings-growth ratio of 0.94 and a beta of 0.62.

CVS Health (NYSE:CVS) last issued its quarterly earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 EPS for the quarter, beating the consensus estimate of $2.21 by $0.36. The firm had revenue of $100.43 billion during the quarter, compared to analysts’ expectations of $94.99 billion. CVS Health had a return on equity of 11.88% and a net margin of 0.72%.The business’s quarterly revenue was up 6.2% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.25 earnings per share. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. Analysts predict that CVS Health Corporation will post 7.44 earnings per share for the current fiscal year.

CVS Health Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, May 4th. Shareholders of record on Thursday, April 23rd were paid a $0.665 dividend. The ex-dividend date was Thursday, April 23rd. This represents a $2.66 annualized dividend and a yield of 2.8%. CVS Health’s dividend payout ratio is currently 117.18%.

Key Headlines Impacting CVS Health

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: CVS Health was upgraded to a Zacks Rank #2 (Buy), reflecting improved earnings optimism and adding to the bullish tone around the stock. Article Title
• Positive Sentiment: Broker sentiment remains constructive on CVS Health, with recent coverage pointing to favorable views from Wall Street analysts and broader confidence in the company’s outlook. Article Title
• Positive Sentiment: The managed-care group rallied after analysts cited softer medical cost and utilization trends across the sector, which can support margins and spill over positively to CVS Health. Article Title
• Neutral Sentiment: CVS Health highlighted community and affordable-housing projects in New Jersey and Massachusetts, underscoring its corporate social responsibility efforts, but these announcements are unlikely to move the stock materially. Article Title
• Neutral Sentiment: Media coverage noted CVS Health is up about 8.5% since its last earnings report and asked whether the rally can continue, mainly reflecting investor attention on post-earnings momentum rather than a new catalyst. Article Title
• Neutral Sentiment: CVS CEO comments on AI, “super apps,” and primary care suggest longer-term strategy focus, but there was no immediate financial update in the coverage. Article Title
• Neutral Sentiment: Additional community partnership news, including a job training lab in Lincoln Heights, is supportive of the brand but not a direct earnings driver. Article Title

Analysts Set New Price Targets

CVS has been the subject of several recent research reports. JPMorgan Chase & Co. upped their price objective on CVS Health from $101.00 to $111.00 and gave the stock an “overweight” rating in a research report on Tuesday, May 12th. Argus upped their price objective on CVS Health from $90.00 to $104.00 and gave the stock a “buy” rating in a research report on Thursday, May 14th. Wolfe Research reduced their price objective on CVS Health from $100.00 to $97.00 and set an “outperform” rating for the company in a research report on Monday, March 2nd. HSBC upped their price objective on CVS Health from $83.00 to $85.00 and gave the stock a “hold” rating in a research report on Tuesday, May 5th. Finally, Wells Fargo & Company upped their price objective on CVS Health from $102.00 to $103.00 and gave the stock an “overweight” rating in a research report on Friday, May 8th. Twenty-two analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat, CVS Health presently has an average rating of “Moderate Buy” and an average target price of $99.88.

Insider Activity at CVS Health

In other CVS Health news, Director Larry Robbins sold 370,462 shares of the company’s stock in a transaction that occurred on Thursday, May 21st. The stock was sold at an average price of $93.45, for a total value of $34,619,673.90. Following the sale, the director owned 4,824,799 shares in the company, valued at $450,877,466.55. This represents a 7.13% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Tilak Mandadi sold 69,551 shares of the company’s stock in a transaction that occurred on Friday, May 8th. The shares were sold at an average price of $89.58, for a total value of $6,230,378.58. Following the completion of the sale, the executive vice president owned 10,133 shares in the company, valued at $907,714.14. This represents a 87.28% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 3,441,551 shares of company stock worth $323,703,977 in the last 90 days. Corporate insiders own 0.85% of the company’s stock.

About CVS Health

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.